Mar 28, 2023 / 12:30PM GMT
Operator
Good day and thank you for standing by. Welcome to the Biomea Conference Call and Webcast to Discuss the Clinical Data from the First Two Cohorts of BMF-219 in Patients with Type 2 Diabetes. (Operator Instructions).
I would like to turn the conference over to your speaker today, Ramses Erdtmann. Please go ahead.
Ramses Erdtmann - Biomea Fusion - Chief Operating Officer & Co-Founder
Thank you, operator. Good morning, everyone, and thank you for dialing in at this early hour. We're excited to discuss with you the press release we issued earlier today and the initial top line data from the first dosing cohorts from our ongoing Phase 1/2 study of BMF-219 in healthy volunteers and Type 2 diabetes patients, also known as COVALENT-111.
Today marks a very big milestone for the Biomea team, as these are the very first ever clinical data we have reported as a company, the first of what we anticipate will be many clinical readouts.
Some quick introductions, my name is Ramses Erdtmann. I'm the COO, president and co-founder of Biomea. With me
Biomea Fusion Inc to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes- Conference Call Transcript
Mar 28, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers